CDI Clinical Trial
Official title:
Prospective, Randomized, Double-Blind, Trial of Oral Vancomycin Therapy Compared to Placebo As Primary Prevention for C. Difficile-associated Infection (CDI)
The purpose of this research study is to determine in patients receiving intravenous (IV) antibiotic(s), if giving oral vancomycin therapy will prevent C. difficile-associated infection (commonly called CDI). Oral vancomycin is an antibiotic that is commonly used to treat CDI. The investigators want to study if using this drug can prevent the development of CDI while you are in the hospital receiving IV antibiotics. The key risk factors for developing CDI are age and IV antibiotic therapy. CDI is an infection in your colon caused by an organism called Clostridium difficile (or C. diff for short) that causes diarrhea. Up to 12% of hospital-acquired infections have been reported to be CDI. It can lead to longer hospital stays and more costs associated with the hospital stay.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03462459 -
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
|
Phase 2 | |
| Completed |
NCT05508607 -
Precision Antimicrobial STewardship for Clostridioides DIfficile Prevention
|
||
| Completed |
NCT03497806 -
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
|
Phase 2 | |
| Completed |
NCT03621657 -
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
|
Phase 2 | |
| Recruiting |
NCT04100603 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection
|
||
| Completed |
NCT03788434 -
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 2 | |
| Not yet recruiting |
NCT06237452 -
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 3 |